Clinical Trial Update: High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose interleukin-2 in combination with an anti-PD-1 therapy to overcome resistance in metastatic melanoma and metastatic renal cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Aldesleukin (Interleukin-2) (Interleukin-2)
• Anti-PD-1 antibody

Snippet

Sponsor: Gregory Daniels | Conditions: Melanoma Stage Iv, Renal Cell Carcinoma, Metastatic | Phase 2 | Status: TERMINATED